Albuminuria, Disease Duration, and Glycated Hemoglobin Are Related With Bone Mineral Density in Type 1 Diabetes: A Cross-sectional Study.

OBJECTIVE: Studies have found a significant decrease in bone mineral density (BMD) in individuals with type 1 diabetes (T1D) compared to healthy controls. Factors associated with this phenomenon have yet to be defined; therefore, this study aimed to explore the association of glycated hemoglobin (HbA1c), disease duration, albuminuria, and glomerular filtration rate with BMD in adults with T1D. METHODS: A cross-sectional study was carried out in tertiary care center. BMD analysis was performed by dual x-ray absorptiometry. Linear models were constructed considering variables associated with BMD. Approval from the ethics committees and informed consent were obtained. RESULTS: We included 128 participants, of whom 59% were women, and 16% had menopause. The median age was 33 (26-42) years. The average age of diabetes diagnosis was 15.3 ± 6.3 years, and the median disease duration was 19.5 (12-27) years. In the adjusted analysis, higher albuminuria (P < .01) and disease duration (P < .05) were associated with a lower BMD in the femoral neck and total hip, independently of age, sex, and body mass index (BMI). Higher HbA1c (P < .01) was associated with a lower spine BMD after adjustment for age, sex, and BMI. CONCLUSION: Studied factors specific to T1D, including albuminuria, disease duration, and HbA1c have an association with BMD regardless of BMI, age, and sex.

[Male aged 31 years with polyneuropathy, prostration, and hypogonadism]. / Hombre de 31 años con polineuropatía, postración e hipogonadismo.

We present the case of a 31 year-old male patient, who presented polyneuropathy, symmetrical, ascending, and progressive, that led to prostration of eight months duration, accompanied by hypogonadism, hypothyroidism, hyperprolactinemia, and the presence of multiple erythematous nodules on the skin. The MRI showed hypointense lesions in the vertebrae T-6 and L-4 with sclerotic appearance. The bone marrow biopsy reported the presence of 12% plasma cells with A. restriction, supporting monoclonal gammopathy (plasmocytoma).

[Degree of control of cardiovascular risk factors among a patient population with diabetes mellitus type 1 and 2]. / Grado de control de factores de riesgo cardiovascular en una población de pacientes con diabetes mellitus tipo 1 y 2 de difícil manejo.

OBJECTIVE: To evaluate the degree of control of metabolic goals in a group of very selected type 1 and 2 diabetic patients. METHODS: A cross-sectional and descriptive study was done. Patients were enrolled consecutively in the Diabetes Clinic in a tertiary-care hospital in México City during the period between april and july 2005. The population at this clinic is very selected as demonstrated by the fact that all type 2 diabetic patients were treated with drugs for diabetic control, including insulin in 43% of them. We used the goals recommended by the American Diabetes Association (ADA) as parameters to analyze and additionally included non-HDL cholesterol and the atherogenic index. RESULTS: A total of 530 patients were included; 468 (58.8% female) had type 2 diabetes, with an average age of 58.5 years; 62 (65% female) patients had type 1 diabetes, with an average age of 31.2 years. The mean HbA1c values were 10.2 +/- 2.8 and 9.0 +/- 2.4 in type 1 and type 2 diabetic patients, respectively. The proportion of diabetic type 1 and 2 patients reaching treatment goals were 12.9% and 23.7% for HbA1c (p=0.02), 82.2% and 57.2% for both systolic and diastolic blood pressure (p=0.0001), 75.8% and 49.3% for triglycerides (p=0.0001), 45.1% and 35.6% for LDL-c (p=0.16), 51.6% and 53.4% for HDL-c (p=0.79), 56.4% and 43.3% for non-HDL cholesterol (p=0.03) and 58.0% and 55.1% for atherogenic index (p=0.66), respectively. The proportion of patients reaching all the optimal treatment goals (non-HDL cholesterol, HbA1c, arterial blood pressure and triglycerides) was 6.4% for type 1 diabetic patients and 4.4% for type 2 patients (p=0.6). Factors associated with achieving goal values in a multiple regression analysis were drug treatment for high blood pressure, use of lipid lowering drugs, insulin use and a history of stroke. CONCLUSIONS: Our results are not comparable with other publications of series evaluating the same parameters in open populations. The results show that the degree of control of evaluated risk factors is not good, principally in the case of glucemic control; it is necessary to plan strategies that help to reach these goals in diabetic patients.

Diabetes in developing countries.

There has been a rapid escalation of type 2 diabetes (T2D) in developing countries, with varied prevalence according to rural vs urban habitat and degree of urbanization. Some ethnic groups (eg, South Asians, other Asians, and Africans), develop diabetes a decade earlier and at a lower body mass index than Whites, have prominent abdominal obesity, and accelerated the conversion from prediabetes to diabetes. The burden of complications, both macro- and microvascular, is substantial, but also varies according to populations. The syndemics of diabetes with HIV or tuberculosis are prevalent in many developing countries and predispose to each other. Screening for diabetes in large populations living in diverse habitats may not be cost-effective, but targeted high-risk screening may have a place. The cost of diagnostic tests and scarcity of health manpower pose substantial hurdles in the diagnosis and monitoring of patients. Efforts for prevention remain rudimentary in most developing countries. The quality of care is largely poor; hence, a substantial number of patients do not achieve treatment goals. This is further amplified by a delay in seeking treatment, "fatalistic attitudes", high cost and non-availability of drugs and insulins. To counter these numerous challenges, a renewed political commitment and mandate for health promotion and disease prevention are urgently needed. Several low-cost innovative approaches have been trialed with encouraging outcomes, including training and deployment of non-medical allied health professionals and the use of mobile phones and telemedicine to deliver simple health messages for the prevention and management of T2D.

Successful Multimodal Treatment of an IGF2-Producing Solitary Fibrous Tumor With Acromegaloid Changes and Hypoglycemia.

Doege-Potter syndrome with acromegaloid facial changes is extremely rare. Uncooked cornstarch along with glucocorticoids have been used as supportive care in patients with non-islet cell tumor hypoglycemia (NICTH). Preoperative embolization of hepatic solitary fibrous tumors (SFT) with NICTH has yielded unsatisfactory results. Herein we present the case of a 61-year-old man with a 3-month history of severe frequent hypoglycemic episodes and acromegaloid facial changes. During a spontaneous hypoglycemia (26 mg/dL), laboratory values showed a hypoinsulinemic pattern with low levels of GH, IGFPB3, and an IGF2/IGF1 ratio of 8.5:1. Cross-sectional imaging revealed a large (16 × 13 × 11 cm) hepatic tumor, and cytology was consistent with SFT. A preoperative right portal embolization was performed in an effort to induce normal remnant liver hypertrophy to allow for safe tumor resection. After the procedure, uncooked starch treatment followed by prednisone was started, achieving complete remission of hypoglycemic episodes in the preoperative setting. He subsequently underwent partial hepatectomy. The histologic diagnosis was compatible with a potentially malignant SFT. The patient had an excellent outcome with complete remission of hypoglycemia, improvement of facial acromegaloid changes, and no further evidence of disease. To our knowledge, this is the first case of a patient with Doege-Potter syndrome with acromegaloid facial changes induced by a potentially malignant liver SFT, treated successfully with a multimodal approach consisting of uncooked cornstarch, low-dose prednisone, preoperative embolization, and complete surgical resection. The use of cornstarch and low-dose glucocorticoids may be an adequate treatment in advance of undergoing surgery.

High prevalence of hypovitaminosis D in Mexicans aged 14 years and older and its correlation with parathyroid hormone.

UNLABELLED: A sample of 585 healthy subjects 14 years and older was studied to estimate the status of 25-hydroxyvitamin D (25(OH)D) and its correlation with parathyroid hormone in healthy Mexicans. In 43.6 % of the sample, levels of vitamin D were below 20 ng/mL and showed an inverse relationship with parathyroid hormone (PTH; p < 0.01). PURPOSE: The purpose of the present study was to estimate the status of 25-hydroxyvitamin D (25(OH)D) and its correlation with parathyroid hormone in healthy Mexicans. METHODS: A cross-sectional study of 585 healthy subjects 14 years and older was carried out. A questionnaire including all relevant demographics, medical history, and lifestyle factors was applied by trained interviewers. Morning fasting blood was collected in all subjects for estimation of 25(OH)D using liquid chromatography-tandem mass spectrometry and PTH hormone-intact molecule by RIA. RESULTS: Of the group of 585 subjects, 54.1 % were women; the sample was divided in three age groups (14-29, 30-50, and >51). Only 9.6 % of the total sample had levels of 25(OH)D above 30 ng/mL; 46.8 % were between 20 and 29 ng/mL, and 43.6 % were below 20 ng/mL. Regarding PTH, a three-phase model was identified using regression smoothing scatterplot (LOESS), with two thresholds of 25(OH)D of 19 and 29 ng/mL. Phase 1 (25(OH)D <19 ng/mL) showed an inverse relationship with PTH (p < 0.01); phases 2 and 3 showed no significant relationship. CONCLUSION: Our results show that 43.6 % of the Mexicans in this study have deficient concentration levels of vitamin D. The cutoff point of 20 ng/mL of 25(OH)D established by the Institute of Medicine has a biological and statistically significant relationship with PTH levels in the Mexican population, independently of principal confounding factors. Like many other countries, Mexico could be included in the global epidemic of hypovitaminosis D.

Myelolipoma: A New Adrenal Finding in Carney's Complex?

Pigmented nodular cortical hyperplasia. a rare cause of Cushing's syndrome, is characterized by resistance to inhibition with dexamethasone and normal sized adrenal glands with multiple, small, pigmented nodules. The disorder may be a component of a syndrome inherited as an autosomal dominant pattern that includes intra- and extracardiac myxomas, lentiginous lesions, blue nevi, other functional endocrire tumors, and perppheral nerve tumors (Carney's complex). We report a patient in whom bilateral myelolipomas were found, in addition to the usual features of this complex. A 29-yr old man was admitted to the hospital for Cushing's syndrome of probably more than 15 yr duration. Physical examination showed diffuse facial hyperchromatic macules. 02-05 cm, predominantly around the lips and on the palmar surfaces of the fingers. Results with dexamethasone suppression nocturnal testing (1 and 8 mg) were compatible with an adrenal adenoma. The computed tomography (CT) of the sella turcica was normal. Adrenal CT showed a tumor in the left gland with a double component one solid and another suggestive of fat, consistent with an angiomyelolipoma. Following 5 wk treatment with ketoconazole, 800 mg per day po, serum cortisol decreased to 5.9 Ag/dL. morning and evening, respectively. Bilateral adrenalectomy was performed. Pathologic examination revealed pigmented nodular cortical hyperplasia and a dominant myelolipoma in the left adrenal. A microscopic myelolipoma was identified in the right adrenal. An echocardiogram showed a mass on the posterior wall of the left ventricle which was a myxoma. Study of the patient's family disclosed two sisters with facial lentigines. Echocardiograms were performed on all available first degree relatives: all were normal. Nocturnal inhibition with dexamethasone revealed that one of the patient's sisters with lentigines also had hypercortisolism. Myelolipoma has been reported in association to Cushing syndrome in humans and experimentally after pituitary extracts in animals. The relationship between this finding and the Carney's complex remain elusive.

Grado de control de factores de riesgo cardiovascular en una población de pacientes con diabetes mellitus tipo 1 y 2 de difícil manejo / Degree of control of cardiovascular risk factors among a patient population with diabetes mellitus type 1 and 2

Objetivo: Evaluar la medida en que se alcanzan las metas de control en un grupo de pacientes seleccionados con diabetes tipo 1 o 2. Métodos: Estudio transversal y descriptivo en el que se incluyeron pacientes atendidos de manera consecutiva en la Consulta Externa de Diabetes del Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán entre abril y julio de 2005; la población seleccionada era de difícil control metabólico; todos los pacientes con diabetes mellitus tipo 2 recibían fármacos para controlar la glucemia, incluyendo insulina en 43% de ellos. Analizamos los criterios de control recomendados por la Asociación Americana de Diabetes, las cifras de colesterol no-HDL y el índice aterogénico. Resultados: Se incluyeron 530 pacientes: 468 (mujeres 58.8%) tenían diabetes tipo 2, con edad promedio de 58.5 años, y 62 (mujeres 65%) tenían diabetes tipo 1, con edad promedio de 31.2 años. El valor promedio de HbA1c fue de 10.2±2.8 y 9.0±2.4 para diabéticos tipo 1 y tipo 2. Las proporciones de pacientes con diabetes tipos 1 y 2 dentro de las metas de tratamiento fueron de 12.9 y 23.7% para HbA1c (p=0.02), 82.2 y 57.2% para presión arterial sistólica y diastólica (p=0.0001), 75.8 y 49.3% para triglicéridos (p=0.0001), 45.1 y 35.6% para c-LDL (p=0.16), 51.6 y 53.4% para c-HDL (p= 0.79), 56.4 y 43.3% para c-no-HDL (p=0.03) y 58.0% versus 55.1% para índice aterogénico (p=0.66). La proporción de pacientes que alcanzaron metas de colesterol no-HDL, HbA1c, presión arterial y triglicéridos fue de 6.4% para diabéticos tipo 1 y de 4.4% para diabéticos tipo 2 (p=0.6). En el análisis de regresión logística múltiple, las variables asociadas con mayor probabilidad de alcanzar las metas de control fueron el tratamiento con antihipertensivos, el uso de hipolipemiantes, de insulina y el antecedente de enfermedad vascular cerebral. Conclusiones: Si bien nuestros resultados no pueden ser directamente comparables con los publicados en otras series en poblaciones abiertas, muestran que el grado de control de los factores de riesgo considerados no es aceptable, sobre todo en los niveles de glucemia; es necesario implementar programas que ayuden a cumplir estas metas en pacientes diabéticos.

OBJECTIVE: To evaluate the degree of control of metabolic goals in a group of very selected type 1 and 2 diabetic patients. METHODS: A cross-sectional and descriptive study was done. Patients were enrolled consecutively in the Diabetes Clinic in a tertiary-care hospital in México City during the period between april and july 2005. The population at this clinic is very selected as demonstrated by the fact that all type 2 diabetic patients were treated with drugs for diabetic control, including insulin in 43% of them. We used the goals recommended by the American Diabetes Association (ADA) as parameters to analyze and additionally included non-HDL cholesterol and the atherogenic index. RESULTS: A total of 530 patients were included; 468 (58.8% female) had type 2 diabetes, with an average age of 58.5 years; 62 (65% female) patients had type 1 diabetes, with an average age of 31.2 years. The mean HbA1c values were 10.2 +/- 2.8 and 9.0 +/- 2.4 in type 1 and type 2 diabetic patients, respectively. The proportion of diabetic type 1 and 2 patients reaching treatment goals were 12.9% and 23.7% for HbA1c (p=0.02), 82.2% and 57.2% for both systolic and diastolic blood pressure (p=0.0001), 75.8% and 49.3% for triglycerides (p=0.0001), 45.1% and 35.6% for LDL-c (p=0.16), 51.6% and 53.4% for HDL-c (p=0.79), 56.4% and 43.3% for non-HDL cholesterol (p=0.03) and 58.0% and 55.1% for atherogenic index (p=0.66), respectively. The proportion of patients reaching all the optimal treatment goals (non-HDL cholesterol, HbA1c, arterial blood pressure and triglycerides) was 6.4% for type 1 diabetic patients and 4.4% for type 2 patients (p=0.6). Factors associated with achieving goal values in a multiple regression analysis were drug treatment for high blood pressure, use of lipid lowering drugs, insulin use and a history of stroke. CONCLUSIONS: Our results are not comparable with other publications of series evaluating the same parameters in open populations. The results show that the degree of control of evaluated risk factors is not good, principally in the case of glucemic control; it is necessary to plan strategies that help to reach these goals in diabetic patients.

Frontiers in internal medicine

Clinical research in Internal Medicine has provided may scientific advances during the past few years. However, the newly generated information overrides the time available to read all of the medial literature regarding advances in Internal Medicine. The goal of this review is to summarize some of the most relevant improvements in clinical practice published over the last few years. From Cardiology to Pulmonary, the authors of this review expose in a succinct way what they and many of their peers consider to be the most trascendental information gathered from thousands of publications. The authors of this review article have attempted to avoid sensationalism by incluiding facts instead of just simply optimistic preliminary findings that can mislead clinicians' decision making. The review is focused on information obtained through well-designed, prospective clinical trials and cohorts where the effectiveness of medical interventions and diagnostic procedures were tested